Opportunity Information: Apply for PAR 14 088
Apply for PAR 14 088
- The National Institutes of Health in the education health income security and social services sector is offering a public funding opportunity titled "Direct Phase II SBIR Grants to Support Biomedical Technology Development" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.172 Human Genome Research 93.173 Research Related to Deafness and Communication Disorders 93.233 National Center on Sleep Disorders Research 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.307 Minority Health and Health Disparities Research 93.350 National Center for Advancing Translational Sciences 93.351 Research Infrastructure Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research 93.867 Vision Research.
- This funding opportunity was created on Feb 19, 2014 and posted on Feb 5, 2014.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Direct Phase II SBIR Grants to Support Biomedical Technology Development" (Funding Opportunity Number PAR-14-088) is a National Institutes of Health (NIH) funding announcement designed to speed up biomedical technology development by letting qualified small businesses move straight into a Phase II Small Business Innovation Research (SBIR) award. Instead of requiring a separate Phase I project first, this "Direct to Phase II" mechanism targets companies that have already done enough early work to credibly show the scientific and technical merit of their concept and the feasibility of a prototype-stage effort. In practical terms, NIH is looking for small business concerns that can demonstrate they have already completed the kind of early research and development (R and D) evidence typically produced during a Phase I (R43) SBIR, and are ready to pursue the more advanced, development-focused goals that fit Phase II.
The purpose behind the FOA is to facilitate SBIR-type R and D, broaden R and D opportunities for eligible small businesses, and increase the pace of technology development and commercialization. The emphasis on commercialization is central: NIH is not just funding basic research here, but technology development that can realistically move toward a product, service, or platform with market potential in the biomedical and health-related space. This makes the program especially relevant for companies that have reduced core technical risk already (for example, through prior internal R and D, prior non-SBIR funding, pilot studies, feasibility data, prototype iterations, or other credible proof-of-concept work) and need Phase II-level support to push the technology further along the development pathway.
This opportunity is a discretionary grant program and uses a grant funding instrument. The activity categories listed for the opportunity span several public service areas, including education, health, income security, and social services, reflecting the broad health mission NIH supports. The eligible applicant pool is limited to small businesses in the United States. Foreign (non-U.S.) entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. That said, foreign components as defined by the NIH Grants Policy Statement may be allowed in some cases, which generally means certain project elements could be carried out abroad if well-justified and compliant with NIH policy, even though the applicant organization itself must be a U.S. small business.
The scope of biomedical topics potentially covered is very broad, which is reflected in the long list of associated CFDA numbers. These include areas such as oral health, human genome research, deafness and communication disorders, sleep disorders, mental health, alcohol research, drug abuse and addiction, technological innovations to improve human health, minority health and health disparities, translational science, research infrastructure, and a wide range of cancer research domains (prevention, detection, diagnosis, treatment, biology, and control). It also includes cardiovascular, lung, blood, arthritis and musculoskeletal/skin diseases, neurological and neuroscience research, allergy and infectious diseases, microbiology and infectious diseases, child health and human development, aging, and vision research. In effect, this FOA can support many types of biomedical technologies as long as they align with NIH institute and center missions and meet the Direct to Phase II readiness expectation.
Administratively, the FOA was posted on February 5, 2014, with a creation date of February 19, 2014. The original closing date and the current closing date listed are both January 7, 2017, and the archive date is February 7, 2017, meaning the announcement is no longer active for new submissions under that specific FOA version. The program did not require cost sharing or matching. For applicants or readers seeking the full historical announcement text, NIH provided an additional information link to the NIH grants guide page for PAR-14-088. For technical issues accessing the announcement, the listed contact was the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV).
Overall, PAR-14-088 was built for U.S. small businesses that can document strong feasibility and prototype-stage progress and want to accelerate into Phase II-level development work aimed at bringing a biomedical technology closer to commercialization. It effectively recognizes that some companies reach Phase I-like milestones through other means and should not be forced to repeat an entire Phase I award cycle before pursuing the more substantial development activities typically supported in Phase II.
FAQs: Direct Phase II SBIR Grants to Support Biomedical Technology Development (PAR-14-088)
What is the title of this grant opportunity?
The funding opportunity is titled "Direct Phase II SBIR Grants to Support Biomedical Technology Development".
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-14-088.
Which agency is offering this opportunity?
This opportunity is offered by the National Institutes of Health (NIH).
What is the main purpose of this FOA?
The FOA is designed to speed up biomedical technology development by allowing qualified small businesses to move directly into a Phase II SBIR award when they can demonstrate they have already completed Phase I-type feasibility work through other means.
What does "Direct to Phase II" mean in this program?
"Direct to Phase II" means an applicant can seek a Phase II-level SBIR award without first completing a separate Phase I (R43) SBIR project, as long as the company can credibly show it already has the early evidence typically generated during Phase I.
Who is this FOA intended for?
It is intended for U.S. small business concerns that have already reduced key scientific and technical risks and are ready for prototype-stage, development-focused Phase II work.
What kind of prior work is NIH expecting applicants to have completed?
NIH is looking for applicants that can demonstrate Phase I-equivalent feasibility and merit through credible prior work, such as internal R and D, prior non-SBIR funding, pilot studies, feasibility data, prototype iterations, or other proof-of-concept evidence showing readiness for Phase II development.
Does this FOA fund basic research or technology development?
Based on the description provided, the emphasis is on SBIR-type R and D that advances biomedical technology development, with a strong focus on commercialization potential rather than purely basic research.
How important is commercialization to this opportunity?
Commercialization is described as central to the program. NIH is seeking technology development that can realistically move toward a product, service, or platform with market potential in biomedical and health-related areas.
What funding instrument is used for this opportunity?
This is a discretionary grant program and uses a grant funding instrument.
Is cost sharing or matching required?
No. The program description states that it did not require cost sharing or matching.
Who is eligible to apply?
The eligible applicant pool is limited to small businesses in the United States.
Are foreign (non-U.S.) organizations eligible to apply?
No. Foreign (non-U.S.) entities are not eligible to apply under this FOA.
Are non-U.S. components of U.S. organizations eligible?
No. The description states that non-U.S. components of U.S. organizations are also not eligible.
Can any part of the project be performed outside the United States?
Possibly. The description notes that foreign components (as defined by the NIH Grants Policy Statement) may be allowed in some cases when well-justified and compliant with NIH policy, even though the applicant organization must be a U.S. small business.
What topic areas does this FOA support?
The scope is described as very broad and tied to NIH institute and center missions. Examples mentioned include oral health; human genome research; deafness and communication disorders; sleep disorders; mental health; alcohol research; drug abuse and addiction; technological innovations to improve human health; minority health and health disparities; translational science; research infrastructure; and extensive cancer research areas (prevention, detection, diagnosis, treatment, biology, and control).
Does the FOA also cover cardiovascular, neurological, infectious disease, aging, and vision-related technologies?
Yes. The description explicitly references topic areas including cardiovascular, lung, and blood; arthritis and musculoskeletal/skin diseases; neurological and neuroscience research; allergy and infectious diseases (including microbiology and infectious diseases); child health and human development; aging; and vision research.
How does NIH describe the advantage of this Direct to Phase II approach?
The FOA recognizes that some companies reach Phase I-like milestones through other funding or internal work, and it is designed so they are not forced to repeat an entire Phase I award cycle before pursuing Phase II-level development activities.
When was this FOA posted and created?
It was posted on February 5, 2014, with a creation date of February 19, 2014.
What were the closing date and current closing date listed for PAR-14-088?
Both the original closing date and the current closing date listed are January 7, 2017.
Is this FOA still active?
No. The description indicates an archive date of February 7, 2017, meaning the announcement is no longer active for new submissions under that specific FOA version.
Where can someone find the full historical announcement text?
NIH provided an additional information link to the NIH grants guide page for PAR-14-088 for the full historical announcement text.
Who was listed as a contact for technical issues accessing the announcement?
The listed contact for technical issues was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Which public service activity categories were associated with this opportunity?
The activity categories listed span several public service areas, including education, health, income security, and social services, reflecting NIH's broad health mission.
What is the key readiness expectation for applicants?
The key expectation is that applicants can document strong feasibility and prototype-stage progress and are prepared to pursue advanced, development-focused Phase II goals consistent with an SBIR Phase II effort.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health Income Security and Social Services
Next opportunity: Alzheimers Disease Pilot Clinical Trials (R01)
Previous opportunity: Agricultural Water Conservation and Efficiency Grants
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 088
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 088) also looked into and applied for these:
| Funding Opportunity |
|---|
| Design and Development of Novel Technologies for Healthy Independent Living (R21) Apply for PAR 14 119 Funding Number: PAR 14 119 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Technologies for Healthy Independent Living (R01) Apply for PAR 14 118 Funding Number: PAR 14 118 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| NIH Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences (R25) Apply for RFA NS 14 010 Funding Number: RFA NS 14 010 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3) Apply for PAR 14 210 Funding Number: PAR 14 210 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (UH3) Apply for PAR 14 211 Funding Number: PAR 14 211 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3) Apply for PAR 14 212 Funding Number: PAR 14 212 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Pre application for the NIH Industry Program Discovering New Therapeutic Uses for Existing Molecules (X02) Apply for PAR 14 213 Funding Number: PAR 14 213 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Chronic Overlapping Pain Conditions (R21) Apply for PA 14 243 Funding Number: PA 14 243 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Basic Research on HIV Persistence (R21) Apply for PAR 14 248 Funding Number: PAR 14 248 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Basic Research on HIV Persistence (R01) Apply for PAR 14 247 Funding Number: PAR 14 247 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of in vivo Chemical Probes (R01) Apply for PAR 14 279 Funding Number: PAR 14 279 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| U.S. China Program for Research Toward a Cure for HIV/AIDS (R01) Apply for RFA AI 14 057 Funding Number: RFA AI 14 057 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $1,350,000 |
| High Throughput Screening (HTS) to Discover Chemical Probes (R21) Apply for PAR 14 283 Funding Number: PAR 14 283 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) Apply for PAR 14 292 Funding Number: PAR 14 292 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) Apply for PAR 14 293 Funding Number: PAR 14 293 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition Research Training for Career Development of Junior Faculty in Medical Education Partnership Initiative (MEPI) Institutions (D43) Apply for RFA TW 14 003 Funding Number: RFA TW 14 003 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $600,000 |
| Physical Sciences Oncology Network (PS ON) Physical Sciences Oncology Projects (PS OP) (U01) Apply for PAR 15 021 Funding Number: PAR 15 021 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $500,000 |
| Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) (U01) Apply for RFA HD 15 029 Funding Number: RFA HD 15 029 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $17,975,000 |
| BRAIN Initiative New Technologies and Novel Approaches for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 15 003 Funding Number: RFA NS 15 003 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 15 004 Funding Number: RFA NS 15 004 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 088", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.